Haystack oncology and alliance foundation trials collaborate to use haystack mrd™ technology in phase ii clinical trial for unresectable stage iii nsclc

Baltimore , jan. 8, 2024 /prnewswire/ -- haystack oncology, a quest diagnostics (nyse: dgx) company, has entered into a collaboration with alliance foundation trials, llc (aft) for research use of haystack oncology's personalized mrd technology (haystack mrd™) to analyze therapeutic response and provide molecular insights for aft's interventional, randomized phase ii clinical trial (aft-57) in patients with unresectable stage iii non-small cell lung cancer (nsclc). the aft-57 clinical study is supported by genentech, a member of the roche group, and will explore the efficacy and safety of an anti-pd-l1 atezolizumab (tecentriq®) with or without tiragolumab (anti-tigit) in conjunction with chemoradiotherapy.
DGX Ratings Summary
DGX Quant Ranking